Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia.

Ann Hematol 2012 Dec 16;91(12):1855-60. Epub 2012 Aug 16.

Department of Biopathology, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.

Overexpression, polymorphisms, and mutations of the WT1 gene have been reported in several human tumors including acute myeloid leukemia (AML) and variably correlated with prognosis. Acute promyelocytic leukemia (APL) represents the AML subset disclosing higher WT1 expression levels; however, no WT1 studies specifically focused on APL have been conducted. We screened for the presence of mutations, SNP rs16754, and expression levels of WT1 gene in 103 adult patients with newly diagnosed APL. Fms-like tyrosine kinase (FLT3) mutations were analyzed as well. WT1 mutations were identified in four (4 %) patients. At least one copy of the minor SNP rs16754 allele (WT1(AG) or WT1(GG)) was detected in 30 (29 %) patients. Six patients (6 %) were homozygous for the minor allele (WT1(GG)) and this genotype was associated with higher WT1 mRNA copies (p = 0.018). FLT3 mutations were found in 37 % of patients and correlated with high WT1 mRNA expression (p = 0.004). Patients heterozygous or homozygous for the minor allele and patients homozygous for major (WT1(AA)) allele did not differ in terms of presenting features. In adult APL, WT1 gene mutational and polymorphic profile shows similarities with pediatric AML rather than with adult AML.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-012-1546-7DOI Listing
December 2012

Publication Analysis

Top Keywords

wt1 gene
16
expression levels
12
snp rs16754
12
wt1
9
acute promyelocytic
8
higher wt1
8
flt3 mutations
8
levels wt1
8
rs16754 expression
8
homozygous minor
8
minor allele
8
wt1 mrna
8
patients homozygous
8
promyelocytic leukemia
8
patients
7
mutations
5
copy minor
4
allele
4
patients copy
4
minor snp
4

Similar Publications

Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients.

Ann Hematol 2012 Dec 16;91(12):1845-53. Epub 2012 Oct 16.

Department of Hematology, Hospital Universitari i Politècnic La Fe, Bulevar Sur s/n, CP 46026, Valencia, Spain.

The single nucleotide polymorphism (SNP) rs16754 of the WT1 gene has been previously described as a possible prognostic marker in normal karyotype acute myeloid leukemia (AML) patients. Nevertheless, the findings in this field are not always reproducible in different series. One hundred and seventy-five adult de novo AML patients were screened with two different methods for the detection of SNP rs16754: high-resolution melting (HRM) and FRET hybridization probes. Read More

View Article and Full-Text PDF
December 2012

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.

J Clin Oncol 2010 Feb 28;28(4):578-85. Epub 2009 Dec 28.

Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Purpose: We assessed the prognostic impact of a known single nucleotide polymorphism (SNP) located in the mutational hotspot of WT1 in patients with cytogenetically normal acute myeloid leukemia (CN-AML) in the context of other prognostic markers.

Patients And Methods: WT1 exons 7 and 9 from 249 CN-AML patients from multicenter treatment trials AML-SHG Hannover 0199 (Clinical Trials Identifier NCT00209833) and 0295, and 50 healthy volunteers were analyzed by direct sequencing. NPM1, FLT3, CEBPA, and MLL were assessed for mutations and WT1 expression was quantified. Read More

View Article and Full-Text PDF
February 2010

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Haematologica 2011 Oct 9;96(10):1488-95. Epub 2011 Jun 9.

Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.

Background: The alleles of the Wilms tumor 1 (WT1) polymorphism rs16754 harbor adenine (A) or guanine (G). Recently, rs16754 has been reported to affect the outcome of patients with cytogenetically normal acute myeloid leukemia. To validate this finding, we investigated pretreatment features and outcome associated with rs16754 in a large cohort of patients with cytogenetically normal acute myeloid leukemia. Read More

View Article and Full-Text PDF
October 2011

Wilms tumor gene single nucleotide polymorphism rs16754 predicts a favorable outcome in children with acute lymphoblastic leukemia.

J Cancer Res Clin Oncol 2015 Dec 30;141(12):2221-8. Epub 2015 Jul 30.

Department of Pediatrics, Jena University Hospital, Jena, Germany.

Purpose: Wilms tumor gene single nucleotide polymorphism (WT1 SNP) rs16754 has been described as a favorable risk marker in patients with acute myeloid leukemia. Subsequent studies revealed inconsistent results in both adult and pediatric patients. We analyzed its impact on clinical outcome in children with acute lymphoblastic leukemia (ALL) for the first time. Read More

View Article and Full-Text PDF
December 2015